Apimeds   Report issue

For profit Phase 2 Phase 3
Founded: Seongnam Korea, Republic of (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2009
NCT00949754
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Apimeds, CEO | Apimeds, Inc. | Apimeds, Inc, US Chief Operating Officer

Active Ingredients

Drugs in Phase 3 Trials (2)

histamine (1 trial)

Honeybee venom (apitox) (2 trials)

Drugs in Phase 2 Trials (1)

bee venom (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Inflammation (Phase 3)

Multiple Sclerosis (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3